Core Insights - West Pharmaceutical Services, Inc. will release its third-quarter financial results on October 23, 2025, before market opening, followed by a conference call at 8:00 a.m. Eastern Time to discuss the results and business expectations [1][2]. Company Overview - West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services, supporting both established and emerging drug developers [3]. - The company has over 10,000 team members across 50 sites, including 25 manufacturing facilities worldwide, delivering over 41 billion components and devices annually [3]. - In fiscal year 2024, West generated $2.89 billion in net sales and is traded on the New York Stock Exchange (NYSE: WST), being part of the Standard & Poor's 500 index [4].

Company Overview - West Pharmaceutical Services, Inc. is a global leader in innovative solutions for injectable drug administration, providing high-quality injectable solutions and services [1][2] - The company has over 10,000 team members across 50 sites, including 25 manufacturing facilities worldwide, delivering over 41 billion components and devices each year [1] Financial Performance - In fiscal year 2024, West generated $2.89 billion in net sales [2] Upcoming Events - West will present at multiple investor conferences in September 2025, including: - Wells Fargo 2025 Healthcare Conference on September 3, 2025, in Boston, MA [4] - Deutsche Bank 2025 Healthcare Summit on September 10, 2025, in New York City, NY [4] - Bank of America Global Healthcare Conference on September 24, 2025, in London, UK [4]

Core Insights - West Pharmaceutical Services, Inc. has appointed Robert McMahon as the new Chief Financial Officer (CFO), effective August 4, 2025, succeeding Bernard Birkett who is retiring [1][2] - McMahon has a strong background in the healthcare industry, having served as CFO at Agilent Technologies since 2018 and held executive roles at Hologic and Johnson & Johnson [2][3] - The company generated $2.89 billion in net sales in fiscal year 2024 and is a key player in providing innovative injectable solutions [4] Company Overview - West Pharmaceutical Services, Inc. is a leading provider of high-quality injectable solutions and services, supporting drug developers in the safe delivery of medicines [3] - The company operates over 50 sites globally, including 25 manufacturing facilities, and delivers over 41 billion components and devices annually [3] Leadership Transition - Bernard Birkett will transition to the role of Senior Advisor to the CEO until the end of the year to ensure a smooth handover [1] - McMahon expressed enthusiasm about joining West and contributing to its growth and innovation [3]

Company Overview - West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services, supporting drug developers in ensuring safe and effective delivery of medicines [4] - The company has over 10,000 team members across 50 sites, including 25 manufacturing facilities worldwide, delivering over 41 billion components and devices each year [4] - In fiscal year 2024, West generated $2.89 billion in net sales and is traded on the New York Stock Exchange (NYSE: WST) [5] Upcoming Financial Results - West Pharmaceutical Services will release its second-quarter financial results before the market opens on Thursday, July 24, 2025 [1] - A conference call to discuss the results and business expectations will follow at 8:00 a.m. Eastern Time on the same day [1] Investor Engagement - A live webcast of the conference call will be available, and participants need to register in advance to ask questions [2] - A slide presentation will be accessible in the Investors section of the company's website on the day of the call, with a replay available for approximately 90 days [3]